Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|A-366||A-366 is a peptide drug that specifically inhibits G9a/GLP methyltransferase, which potentially results in reduced H3K9me2 levels and inhibits tumor growth (PMID: 26147105).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||A-366||Preclinical - Cell line xenograft||Actionable||In a preclinical study, A-366 inhibited proliferation and reduced cell viability in an acute myeloid leukemia (AML) cell line in culture, and inhibited tumor growth in an AML cell line xenograft model (PMID: 26147105).||26147105|
|Unknown unknown||acute promyelocytic leukemia||not applicable||A-366||Preclinical - Cell culture||Actionable||In a preclinical study, A-366 inhibited cell proliferation and increased differentiation in an acute promyelocytic leukemia cell line in culture (PMID: 26147105).||26147105|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|